Beneficial Ownership Report · SCHEDULE 13G/A
Capricor Therapeutics, Inc.
CAPRNASDAQEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13G/A
primary_doc.xml
Amendment · This filing reports the amendment as submitted.
Subject company
- Company
- Capricor Therapeutics, Inc.
- Company CIK
- 0001133869
- Street
- 10865 Road to the Cure
- Street (continued)
- Suite 150
- City
- San Diego
- State / country code
- CA
- Postal code
- 92121
Statement details
- Amendment number
- 1
- Security class
- Common Stock, par value $0.001 per share
- Event date
- 09/30/2026
- Rule designation
- Rule 13d-1(c)
Reporting person 1
- Name
- Montanova Capital, LLC
- Citizenship / organization
- DE
- Reporting person type
- IA · OO
- Group designation
- b
- Aggregate amount owned
- 0.00
- Percent of class
- 0
- Sole voting power
- 0.00
- Shared voting power
- 0.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 0.00
- Aggregate excludes certain shares
- N
Reporting person 2
- Name
- Averill Master Fund, Ltd.
- Citizenship / organization
- E9
- Reporting person type
- CO
- Group designation
- b
- Aggregate amount owned
- 0.00
- Percent of class
- 0
- Sole voting power
- 0.00
- Shared voting power
- 0.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 0.00
- Aggregate excludes certain shares
- N
Reporting person 3
- Name
- Aaron Cowen
- Citizenship / organization
- X1
- Reporting person type
- HC · IN
- Group designation
- b
- Aggregate amount owned
- 0.00
- Percent of class
- 0
- Sole voting power
- 0.00
- Shared voting power
- 0.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 0.00
- Aggregate excludes certain shares
- N
Item 1
Issuer
Capricor Therapeutics, Inc.
Principal executive office address
10865 Road to the Cure, Suite 150, San Diego, California 92121
Item 2
Citizenship
Montanova Capital, LLC - Delaware Averill Master Fund, Ltd. - Cayman Islands Aaron Cowen - United States
Filing person
Montanova Capital, LLC Averill Master Fund, Ltd. Aaron Cowen
Principal business or residence address
Montanova Capital, LLC 11 E 26th Street, 16th Floor New York, New York 10010 United States of America Averill Master Fund, Ltd. c/o Maples Corporate Services Limited P.O. Box 309 Ugland House Grand Cayman KY1-1104 Cayman Islands Aaron Cowen c/o Montanova Capital, LLC 11 E 26th Street, 16th Floor New York, New York 10010 United States of America
Item 3
Not applicable indication
Y
Item 4
Percent of class
Montanova Capital, LLC - 0% Averill Master Fund, Ltd. - 0% Aaron Cowen - 00%
Amount beneficially owned
Montanova Capital, LLC - 0 Averill Master Fund, Ltd. - 0 Aaron Cowen - 0
Sole voting power
Montanova Capital, LLC - 0 Averill Master Fund, Ltd. - 0 Aaron Cowen - 0
Shared voting power
Montanova Capital, LLC - 0 Averill Master Fund, Ltd. - 0 Aaron Cowen - 0
Sole dispositive power
Montanova Capital, LLC - 0 Averill Master Fund, Ltd. - 0 Aaron Cowen - 0
Shared dispositive power
Montanova Capital, LLC - 0 Averill Master Fund, Ltd. - 0 Aaron Cowen - 0
Item 5
Not applicable indication
N
Ownership of 5% or less
Y
Item 6
Not applicable indication
N
Ownership on behalf of another person
All of the securities reported in this Schedule 13G Amendment No. 1 are directly owned by advisory clients of Montanova Capital, LLC. None of those advisory clients may be deemed to beneficially own more than 5% of the Common Stock, $0.01 par value.
Item 7
Not applicable indication
N
Subsidiaries
Please see Exhibit B attached hereto.
Item 8
Not applicable indication
Y
Item 9
Not applicable indication
Y
Item 10
Not applicable indication
N
Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
Exhibits
Exhibit A - Joint Filing Agreement Exhibit B - Control Person Identification
Signature comments
* Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his, her or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. To the extent that "ownership of 5 percent or less of a class" was indicated in Item 5, such response only applies to the Reporting Person(s) that indicated elsewhere herein that it beneficially owns five percent (5%) or less of the class.
Signature 1
- Reporting person
- Montanova Capital, LLC
- Signed
- /s/ Andrew Nathanson
- Title
- Andrew Nathanson, General Counsel and Chief Compliance Officer
- Date
- 11/13/2026
Signature 2
- Reporting person
- Averill Master Fund, Ltd.
- Signed
- /s/ Andrew Nathanson
- Title
- Andrew Nathanson, Authorized Signatory
- Date
- 11/13/2026
Signature 3
- Reporting person
- Aaron Cowen
- Signed
- /s/ Aaron Cowen
- Title
- Aaron Cowen
- Date
- 11/13/2026
Filed exhibits
Company context
Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing cell and exosome-based therapeutics for the treatment of rare diseases. Our lead product candidate, Deramiocel, is an allogeneic cardiac-derived cell therapy in late-stage development for the treatment of Duchenne muscular dystrophy, evaluated in clinical studies for its potential to preserve skeletal and cardiac muscle function. Capricor is also advancing its proprietary StealthX™ exosome platform for the targeted delivery of oligonucleotides, proteins, and small-molecule therapeutics across a range of diseases. At Capricor, we are committed to delivering new therapies for patients with rare diseases. For more information, visit capricor.com, and follow Capricor on Facebook, Instagram and X.
Current securities
Historical securities (1)
Recent company filings
- 10-Q filingNov 10, 2026
- Results of Operations and Financial ConditionNov 10, 2026
- SCHEDULE 13G - filed by MILLENNIUM MANAGEMENT LLC regarding CAPRICOR THERAPEUTICS, INC.Sep 14, 2026
- Other EventsAug 24, 2026
- SCHEDULE 13G - filed by MILLENNIUM MANAGEMENT LLC regarding CAPRICOR THERAPEUTICS, INC.Aug 19, 2026